ANTX AN2 Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1880438 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-2.5%
TTM EPS YoY19.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-51.3%
ROA-46.7%
ROIC (approx.)-60.6%
Asset turnover—
Leverage & solvency
Liabilities / assets7.9%
Debt / equity0.00x
Current ratio10.48x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.87x
Accruals ratio-5.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $5.72M | $6.02M | $6.74M | $6.88M | $7.00M | $3.20M | $7.69M | $5.40M |
| SG&A expense | $2.95M | $2.88M | $3.81M | $2.44M | $3.04M | $4.02M | $3.85M | $3.21M |
| Operating income | -$8.67M | -$8.90M | -$10.55M | -$9.32M | -$10.04M | -$7.22M | -$11.54M | -$8.60M |
| Net income | -$7.96M | -$8.19M | -$10.03M | -$8.67M | -$9.35M | -$6.46M | -$10.65M | -$7.52M |
| EPS (basic) | -0.17 | -0.18 | -0.29 | — | -0.31 | -0.21 | -0.35 | — |
| EPS (diluted) | -0.17 | -0.18 | -0.29 | — | -0.31 | -0.21 | -0.35 | — |
| Weighted avg. shares (diluted) | 46.11M | 44.76M | 34.06M | — | 30.28M | 30.17M | 30.05M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $20.21M | $44.32M | $53.49M | $19.94M | $18.00M | $18.22M | $19.98M | $21.35M |
| Short-term investments | $44.19M | $34.07M | $31.80M | $38.06M | $43.92M | $44.70M | $47.08M | $62.27M |
| Current assets | $65.76M | $79.99M | $87.49M | $59.94M | $64.02M | $67.52M | $69.56M | $86.26M |
| Total assets | $81.95M | $81.68M | $87.49M | $61.95M | $67.23M | $75.83M | $81.34M | $92.09M |
| Current liabilities | $6.28M | $5.58M | $5.56M | $8.72M | — | — | — | $10.24M |
| Total liabilities | $6.45M | $5.75M | $5.73M | $8.89M | $6.86M | $6.98M | $8.01M | $10.24M |
| Shareholders' equity | $75.51M | $75.92M | $81.76M | $53.06M | $60.38M | $68.84M | $73.33M | $81.85M |
| Shares outstanding | 37.89M | 36.31M | 35.99M | 27.41M | 27.37M | 27.38M | 30.14M | 29.92M |
| Cash flow statement | ||||||||
| Operating cash flow | -$6.10M | -$7.00M | -$12.07M | -$5.24M | -$6.38M | -$7.60M | -$10.62M | -$5.27M |
| Investing cash flow | -$24.44M | -$3.66M | $8.29M | $7.17M | $6.11M | $5.83M | $9.19M | -$6.88M |
| Financing cash flow | $6.43M | $1.49M | $37.33M | $0 | $48,000 | $0 | $65,000 | $0 |
| Stock-based compensation | $973,000 | $972,000 | $1.46M | $1.40M | $801,000 | $2.00M | $2.05M | $1.78M |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.